Protein binding domains stabilizing functional conformational states of GPCRs and uses thereof

Patent metadata

Field	Value
Publication number	US-9689872-B2
Application number	US-201615236398-A
Country	US
Kind code	B2
Filing date	Aug 13, 2016
Priority date	Jul 16, 2010
Publication date	Jun 27, 2017
Grant date	Jun 27, 2017

Abstract

The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.

First claim

What is claimed is:

1. A method of generating a nanobody, the method comprising:
immunizing a camelid with a GPCR bound to an agonist;
allowing the animal to produce heavy chain only antibodies to the GPCR;
generating a library of nanobodies comprising the variable domains from the produced heavy chain only antibodies; and
screening the library to identify a nanobody that specifically binds to and stabilizes an active conformational state of the GPCR; and wherein the nanobody is able to enhance the affinity of the GPCR for agonists.

2. The method according to claim 1 , wherein the active conformational state of the GPCR comprises the cytoplasmic end of transmembrane segment 6 (TM6) being moved outward and away from the core of the GPCR as compared to the GPCR when not bound to the nanobody.

3. The method according to claim 1 , further comprising screening a complex of the GPCR and the nanobody for increased thermostability as compared to the GPCR when not bound to the nanobody.

4. The method according to claim 1 , further comprising purifying the identified nanobody.

5. The method according to claim 1 , wherein the GPCR is a mammalian protein, a plant protein, a microbial protein, a viral protein, or an insect protein.

6. The method according to claim 1 , wherein the GPCR is a human protein.

7. The method according to claim 1 , wherein the GPCR is selected from the group consisting of a GPCR of the Glutamate family of GPCRs, a GPCR of the Rhodopsin family of GPCRs, a GPCR of the Adhesion family of GPCRs, a GPCR of the Frizzled/Taste2 family of GPCRs, and a GPCR of the Secretin family of GPCRs.

8. The method according to claim 1 , wherein the GPCR is an adrenergic receptor, a muscarinic receptor, or an angiotensin receptor.

9. The method according to claim 1 , wherein the agonist is selected from the group consisting of a small molecule, a protein, a peptide, a protein scaffold, a nucleic acid, an ion, a carbohydrate, an antibody, and any suitable fragment thereof.

Assignees

• Vib Vzw
• Univ Brussel Vrije
• Univ Leland Stanford Junior

Inventors

• Steyaert Jan
• Fung Juan Jose
• Kobilka Brian
• Laeremans Toon
• Pardon Els
• Rasmussen Soren G F

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P35/00

  Antineoplastic agents · CPC title